Black Goji Berry Anthocyanins Eased Parkinson’s Symptoms in Mice by Reshaping Gut Bacteria

Pigments extracted from black goji berries may protect dopamine neurons in Parkinson's disease by reshaping the gut microbiome and redirecting tryptophan metabolism away from neurotoxic compounds. That is the preliminary conclusion of a new mouse study published in June 2026 in the journal International Immunopharmacology, where researchers administered Lycium ruthenicum Murray anthocyanins (LRA) to animals whose Parkinson's-like neurodegeneration was chemically induced. The results are early-stage and require substantial follow-up, but they sketch a specific biological pathway worth watching.

Black Goji Anthocyanins Reversed Motor and Cognitive Deficits in PD Mice

The team, led by Guo H. and colleagues, used MPTP to induce Parkinson's-like neurodegeneration in 66 adult male C57BL/6J mice, then treated different groups with either a placebo, the standard drug Madopar, or LRA at doses of 50, 100, or 200 mg/kg. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) destroys the dopamine-producing neurons of the striatum, replicating the motor deficits and cell death that define Parkinson's disease. Animals treated with the two higher LRA doses (100 and 200 mg/kg) showed meaningfully improved motor coordination, exploratory behavior, and cognitive function compared with untreated MPTP mice. Inflammatory cytokines and oxidative stress markers dropped, and striatal neurotrophic and dopaminergic markers were partially restored. The 50 mg/kg dose produced weaker effects, suggesting a dose-response relationship.

Understanding why this matters requires a brief note on neuroinflammation's central role in Parkinson's disease: the progressive loss of dopaminergic neurons is driven partly by a self-sustaining inflammatory loop, and interventions that interrupt that loop early are among the most actively sought in the field.

Gut Microbiota Dysbiosis Sits at the Heart of the Disease Model

Parkinson's is increasingly understood as a condition with deep roots in the gut. Research on the gut-brain axis and Parkinson's has shown that intestinal microbiome disruption drives abnormal protein aggregation and immune activation that eventually reaches the brain. In the MPTP mice, the gut community was predictably disrupted. LRA treatment partially reversed that disruption, restoring three specific bacterial groups: Lachnospiraceae_NK4A136_group, unclassified Lachnospiraceae, and Parabacteroides. Members of the Lachnospiraceae family are well-known producers of short-chain fatty acids, which help maintain gut barrier integrity and dampen systemic inflammation. The rebalancing of these populations likely contributed to the downstream metabolic changes the researchers observed.

How LRA Rerouted Tryptophan Away From a Neurotoxic Dead End

The most mechanistically specific finding involves tryptophan, an essential amino acid that can be metabolized along several competing routes. In inflammatory states, tryptophan is preferentially shunted through the kynurenine pathway, generating compounds including quinolinic acid and xanthurenic acid. Quinolinic acid is an excitotoxin that damages neurons at elevated concentrations; disturbed tryptophan metabolism and excess quinolinic acid are increasingly implicated in both neuroinflammatory and neurodegenerative conditions. In the LRA-treated mice, levels of quinolinic acid and xanthurenic acid fell, while serotonin and three indole derivatives rose: indole-3-lactic acid, indole-3-acetic acid, and indole-3-propionic acid. These indoles are produced by gut bacteria acting on tryptophan and carry anti-inflammatory and neuroprotective properties. The shift suggests that restoring Lachnospiraceae and Parabacteroides populations redirected tryptophan away from the kynurenine pathway and toward these protective metabolites, forming what the authors describe as a gut microbiota-tryptophan metabolism-neuroprotection axis.

Beyond tryptophan, metabolomic profiling of urine and serum identified 14 urinary and 12 serum key metabolites that shifted with LRA treatment, including tauroursodeoxycholic acid (a bile acid with known neuroprotective properties) and changes in glycerophospholipid metabolism. These additional findings are suggestive but not yet mechanistically resolved.

Why the MPTP Model Has Real Limits for Human Translation

This study is investigational, and the MPTP mouse model carries important caveats. As noted in literature on the limitations of MPTP animal models, the model induces rapid, acute dopaminergic degeneration that does not reflect the slow, decades-long progression of human Parkinson's disease. Critically, this means LRA's ability to reshape gut microbiota over a short dosing window in mice does not straightforwardly predict what would happen in a person whose gut community has been dysbiotic for years. The dose-to-human translation is also unresolved: 100 to 200 mg/kg in mice does not convert cleanly to a dietary or supplement amount achievable in people. The authors themselves characterize the gut microbiota-tryptophan neuroprotection axis as a potential mechanism, flagging the need for further validation. There are no human trials yet.

What Comes Next for LRA Research

The study opens at least two tractable follow-up directions. First, fecal transplant experiments or antibiotic depletion studies could test whether the gut microbiota shifts are causally necessary for the neuroprotective effects, rather than correlates. Second, the identified metabolite shifts, particularly the indole derivatives, could be tested directly in neuronal cell culture and longer-duration animal models to pin down whether they are the active agents. Broader questions remain: whether LRA's effects hold in models that more faithfully replicate slow-progressing Parkinson's, whether sex differences matter given that the current study used only male mice, and what the bioavailability of LRA anthocyanins looks like in humans after digestion. Black goji berry is already consumed as food in parts of Central Asia, which gives future safety research a reasonable starting point, but efficacy in humans will require controlled trials that do not yet exist.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• All findings come from a mouse model of Parkinson's disease; results may not translate to humans.
• No human trials of LRA for Parkinson's disease have been conducted.
• The proposed gut microbiota–tryptophan–neuroprotection axis is mechanistically suggestive, not experimentally proven; causal links were not directly tested.
• Funding was not disclosed, so independent verification of the study's financial independence cannot be confirmed.

Preclinical mouse study (n=66 C57BL/6J mice) using an MPTP-induced Parkinson's disease model. Results show associations between LRA treatment and changes in gut microbiota composition, tryptophan metabolite profiles, and neuroinflammatory markers, but the proposed causal axis was not directly tested and no human data exist. Findings are consistent with prior mechanistic literature on indole derivatives and neuroinflammation but have not been independently replicated in this context.

References

1. HanQing Guo, XueMei Qin, Yun Tang, et al. (2026). Lycium ruthenicum Murray anthocyanins alleviate neuroinflammation in MPTP-induced Parkinson's disease by modulating gut microbiota and tryptophan metabolism. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117051
2. Daniel D. Savage, Martina J. Rosenberg, Laurent Coquet, et al. (2020). Ethanol-Induced Alterations in Placental and Fetal Cerebrocortical Annexin-A4 and Cerebral Cavernous Malformation Protein 3 Are Associated With Reductions in Fetal Cortical VEGF Receptor Binding and Microvascular Density. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2020.00519
3. Qing Li, Ling-bing Meng, Li-jun Chen, et al. (2023). The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson’s disease. Frontiers in Neurology. https://doi.org/10.3389/fneur.2023.1185375
4. Knut Hestad, Jan Alexander, Helge Rootwelt, Jan O. Aaseth (2022). The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. Biomolecules. https://doi.org/10.3390/biom12070998
5. MPTP Parkinsonism and Implications for Understanding Parkinson's Disease – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018260/